Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a $10 price target.
September 12, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Black Diamond Therapeutic and maintained a $10 price target.
The reiteration of an Outperform rating by a reputable analyst like Robert Driscoll from Wedbush is a positive signal for Black Diamond Therapeutic. The maintained price target of $10 also indicates confidence in the company's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100